Based on the evidences that CCL5/CCR5 pathway involves in progression of atherosclerosis or intimal hyperplasia, several studies reported that maraviroc, an antagonist of CCR5, showed decreasing atherosclerosis or intimal hyperplasia [31,32]. Here, CCL5 is linked to atherosclerosis.